{"transactions":[{"id":747512,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:30:52.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":53250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":53250,"derivative":{"exercise_price":2.29,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":53250},"source":{"system":"sec-edgar","filing":"0001628280-26-041273","document":"wk-form4_1780691449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026041273/wk-form4_1780691449.xml","form_type":"4"}},{"id":747511,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:30:52.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":220624,"source":{"system":"sec-edgar","filing":"0001628280-26-041273","document":"wk-form4_1780691449.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026041273/wk-form4_1780691449.xml","form_type":"4"}},{"id":756121,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:30:21.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":42671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":42671,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":42671},"source":{"system":"sec-edgar","filing":"0001709418-26-000002","document":"form4-06022026_040616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000170941826000002/form4-06022026_040616.xml","form_type":"4"}},{"id":756120,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T20:30:21.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":21335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":1176559,"source":{"system":"sec-edgar","filing":"0001709418-26-000002","document":"form4-06022026_040616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000170941826000002/form4-06022026_040616.xml","form_type":"4"}},{"id":1120919,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:59:03.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":19500,"derivative":{"exercise_price":1.07,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001576885-25-000082","document":"wk-form4_1749157011.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000082/wk-form4_1749157011.xml","form_type":"4"}},{"id":1120918,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:59:03.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":12800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual\nstockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":185124,"source":{"system":"sec-edgar","filing":"0001576885-25-000082","document":"wk-form4_1749157011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000082/wk-form4_1749157011.xml","form_type":"4"}},{"id":1123811,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-04T20:15:26.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":113246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":113246,"derivative":{"exercise_price":2.785,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":113246},"source":{"system":"sec-edgar","filing":"0001415889-25-015574","document":"form4-06042025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015574/form4-06042025_040609.xml","form_type":"4"}},{"id":1123810,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:15:26.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":56623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":1155224,"source":{"system":"sec-edgar","filing":"0001415889-25-015574","document":"form4-06042025_040609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015574/form4-06042025_040609.xml","form_type":"4"}},{"id":1350930,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":561797,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 1,123,595  investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":561797,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":561797},"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350929,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":561797,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 1,123,595  investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":561797,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":561797},"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350928,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-26","kind":"gift","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1873800,"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350927,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":1123595,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 1,123,595  investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":1823800,"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1484499,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:49:05.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.62,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001576885-24-000082","document":"wk-form4_1718052537.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000082/wk-form4_1718052537.xml","form_type":"4"}},{"id":1497243,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:18:25.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":98440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":98440,"derivative":{"exercise_price":3.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":98440},"source":{"system":"sec-edgar","filing":"0001415889-24-015041","document":"form4-05312024_040510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015041/form4-05312024_040510.xml","form_type":"4"}},{"id":1497242,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:18:25.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":49220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":1098601,"source":{"system":"sec-edgar","filing":"0001415889-24-015041","document":"form4-05312024_040510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015041/form4-05312024_040510.xml","form_type":"4"}},{"id":1806744,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:53:51.000Z","date":"2023-08-16","kind":"gift","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1049381,"source":{"system":"sec-edgar","filing":"0001209191-23-046152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046152/doc4.xml","form_type":"4"}},{"id":1806743,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:53:51.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":388889,"price":0.9,"value":350000.1,"ownership":{"direct":true},"balance_after":999381,"source":{"system":"sec-edgar","filing":"0001209191-23-046152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046152/doc4.xml","form_type":"4"}},{"id":1806742,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:53:51.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":388889,"price":0.9,"value":350000.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018."}],"balance_after":884290,"source":{"system":"sec-edgar","filing":"0001209191-23-046152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046152/doc4.xml","form_type":"4"}},{"id":1844704,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:48:53.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":43800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":43800,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":43800},"source":{"system":"sec-edgar","filing":"0001209191-23-039730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123039730/doc4.xml","form_type":"4"}},{"id":1863501,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-07T21:45:31.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.2,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001576885-23-000037","document":"wk-form4_1686174319.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000037/wk-form4_1686174319.xml","form_type":"4"}},{"id":2214694,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T20:11:16.000Z","date":"2022-07-05","kind":"purchase","acquired":true,"shares":238095,"price":2.1,"value":499999.5,"ownership":{"direct":true},"balance_after":700205,"source":{"system":"sec-edgar","filing":"0001209191-22-040591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919122040591/doc4.xml","form_type":"4"}},{"id":2226710,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:24:52.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":3.59,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-037875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919122037875/doc4.xml","form_type":"4"}},{"id":2637812,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred","published_at":"2021-07-08T22:17:32.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":131595,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of\nOctober 25, 2018."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":131595},"source":{"system":"sec-edgar","filing":"0001209191-21-046030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919121046030/doc4.xml","form_type":"4"}},{"id":2637811,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred","published_at":"2021-07-08T22:17:32.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":130180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":130180},"source":{"system":"sec-edgar","filing":"0001209191-21-046030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919121046030/doc4.xml","form_type":"4"}},{"id":2637810,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T22:17:32.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":131595,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of\nOctober 25, 2018."}],"balance_after":131595,"source":{"system":"sec-edgar","filing":"0001209191-21-046030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919121046030/doc4.xml","form_type":"4"}},{"id":2637809,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T22:17:32.000Z","date":"2021-07-06","kind":"purchase","acquired":true,"shares":35000,"price":16,"value":560000.0,"ownership":{"direct":true},"balance_after":172324,"source":{"system":"sec-edgar","filing":"0001209191-21-046030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919121046030/doc4.xml","form_type":"4"}},{"id":2637808,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T22:17:32.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":130180,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":137324,"source":{"system":"sec-edgar","filing":"0001209191-21-046030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919121046030/doc4.xml","form_type":"4"}},{"id":2643659,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:20:48.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control."}],"balance_after":34000,"derivative":{"exercise_price":16,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-21-044956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576885/000120919121044956/doc4.xml","form_type":"4"}},{"id":3055950,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-17T20:39:29.000Z","date":"2020-08-14","kind":"purchase","acquired":true,"shares":15700,"price":6.38,"value":100166.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.08 to $6.65, inclusive."}],"balance_after":462110,"source":{"system":"sec-edgar","filing":"0001209191-20-046963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919120046963/doc4.xml","form_type":"4"}},{"id":3055949,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-17T20:39:29.000Z","date":"2020-08-13","kind":"purchase","acquired":true,"shares":15550,"price":6.45,"value":100297.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.24 to $6.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2)."}],"balance_after":446410,"source":{"system":"sec-edgar","filing":"0001209191-20-046963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919120046963/doc4.xml","form_type":"4"}},{"id":3374619,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:40:39.000Z","date":"2019-11-12","kind":"other","acquired":false,"shares":635665,"price":27.5,"value":17480787.5,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-056045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119056045/doc4.xml","form_type":"4"}},{"id":3702009,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-08T01:54:52.000Z","date":"2019-01-07","kind":"purchase","acquired":true,"shares":1200,"price":10.94,"value":13128.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.91 to $11.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":430860,"source":{"system":"sec-edgar","filing":"0001209191-19-002675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919119002675/doc4.xml","form_type":"4"}},{"id":3702008,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-08T01:54:52.000Z","date":"2019-01-07","kind":"purchase","acquired":true,"shares":8021,"price":10.38,"value":83257.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.90 to $10.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":429660,"source":{"system":"sec-edgar","filing":"0001209191-19-002675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919119002675/doc4.xml","form_type":"4"}},{"id":3721373,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-21T17:07:56.000Z","date":"2018-12-20","kind":"purchase","acquired":true,"shares":31000,"price":6.26,"value":194060.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.02\nto $6.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth in footnote (1) to this Form 4."}],"balance_after":635665,"source":{"system":"sec-edgar","filing":"0001209191-18-063954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919118063954/doc4.xml","form_type":"4"}},{"id":3888857,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-06-19T20:50:11.000Z","date":"2018-06-19","kind":"exercise","acquired":false,"shares":394295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":394295},"source":{"system":"sec-edgar","filing":"0001209191-18-038600","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919118038600/doc4.xml","form_type":"4"}},{"id":3888856,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-19T20:50:11.000Z","date":"2018-06-19","kind":"exercise","acquired":true,"shares":394295,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."}],"balance_after":421639,"source":{"system":"sec-edgar","filing":"0001209191-18-038600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919118038600/doc4.xml","form_type":"4"}}]}